Article
Medicine, General & Internal
Tanya Siddiqi, David G. Maloney, Saad S. Kenderian, Danielle M. Brander, Kathleen Dorritie, Jacob Soumerai, Peter A. Riedell, Nirav N. Shah, Rajneesh Nath, Bita Fakhri, Deborah M. Stephens, Shuo Ma, Tatyana Feldman, Scott R. Solomon, Stephen J. Schuster, Serena K. Perna, Sherilyn A. Tuazon, San -San Ou, Eniko Papp, Leanne Peiser, Yizhe Chen, William G. Wierda
Summary: In this study, lisocabtagene maraleucel (liso-cel) was evaluated for its efficacy and safety in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The results showed that liso-cel induced complete response or remission in patients, including those who had previously failed treatment with a BTK inhibitor and venetoclax. The safety profile was manageable.
Article
Oncology
Peter Hillmen, Alexandra Pitchford, Adrian Bloor, Angus Broom, Moya Young, Ben Kennedy, Renata Walewska, Michelle Furtado, Gavin Preston, Jeffrey R. Neilson, Nicholas Pemberton, Gamal Sidra, Nicholas Morley, Kate Cwynarski, Anna Schuh, Francesco Forconi, Nagah Elmusharaf, Shankara Paneesha, Christopher P. Fox, Dena R. Howard, Anna Hockaday, Julia M. Brown, David A. Cairns, Sharon Jackson, Natasha Greatorex, Nichola Webster, Jane Shingles, Surita Dalal, Piers E. M. Patten, David Allsup, Andrew Rawstron, Talha Munir
Summary: This study compares the efficacy of ibrutinib and rituximab with fludarabine, cyclophosphamide, and rituximab in previously untreated chronic lymphocytic leukemia (CLL) patients. The results show that ibrutinib and rituximab significantly improve progression-free survival compared to the standard chemoimmunotherapy.
Article
Oncology
Peter Hillmen, Alexandra Pitchford, Adrian Bloor, Angus Broom, Moya Young, Ben Kennedy, Renata Walewska, Michelle Furtado, Gavin Preston, Jeffrey R. Neilson, Nicholas Pemberton, Gamal Sidra, Nicholas Morley, Kate Cwynarski, Anna Schuh, Francesco Forconi, Nagah Elmusharaf, Shankara Paneesha, Christopher P. Fox, Dena R. Howard, Anna Hockaday, Julia M. Brown, David A. Cairns, Sharon Jackson, Natasha Greatorex, Nichola Webster, Jane Shingles, Surita Dalal, Piers E. M. Patten, David Allsup, Andrew Rawstron, Talha Munir
Summary: This study is an interim analysis comparing the efficacy of ibrutinib and rituximab with fludarabine, cyclophosphamide, and rituximab in previously untreated CLL patients. The results show that ibrutinib and rituximab significantly improve progression-free survival compared to the standard chemoimmunotherapy treatment.
Article
Oncology
Nitin Jain, Philip Thompson, Jan Burger, Alessandra Ferrajoli, Koichi Takahashi, Zeev Estrov, Gautam Borthakur, Prithviraj Bose, Tapan Kadia, Naveen Pemmaraju, Koji Sasaki, Marina Konopleva, Elias Jabbour, Naveen Garg, Xuemei Wang, Rashmi Kanagal-Shamanna, Keyur Patel, Wei Wang, Jeffrey Jorgensen, Sa Wang, Wanda Lopez, Ana Ayala, William Plunkett, Varsha Gandhi, Hagop Kantarjian, Susan O'Brien, Michael Keating, William G. Wierda
Summary: The iFCG regimen with only 3 cycles of chemotherapy is an effective, time-limited regimen for patients with CLL with mutated IGHV and without del(17p)/TP53 mutation. The treatment resulted in high rates of complete remission and undetectable measurable residual disease in the marrow, with excellent 3-year progression-free and overall survival rates.
Article
Hematology
Jeff P. Sharman, Danielle M. Brander, Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster, Suman Kambhampati, John M. Burke, Frederick Lansigan, Marshall T. Schreeder, Scott D. Lunin, Alexander Zweibach, Mikhail Shtivelband, Patrick M. Travis, Jason C. Chandler, Kathryn S. Kolibaba, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Ian W. Flinn
Summary: The study found that adding ublituximab to ibrutinib therapy in high-risk patients resulted in a significantly higher overall response rate without affecting the safety profile of ibrutinib monotherapy.
LANCET HAEMATOLOGY
(2021)
Article
Medicine, General & Internal
Martin Simkovic, Pavel Vodarek, Monika Motyckova, Dominika ecsiova, Petra Rozsivalova, Heidi Mocikova, Pavla Stepankova, Alice Sykorova, Katerina Hrochova, Filip Vrbacky, David Belada, Pavel Zak, Lukas Smolej
Summary: The RCD regimen is an effective treatment option for elderly patients with relapsed CLL, with significant predictors of shorter PFS being TP53 deletion/mutation, advanced Rai stage, and >= 2 previous lines of treatment. The addition of cyclophosphamide to the R-Dex regimen maintains similar efficacy, even with a 50% reduction in the dexamethasone dose.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Oncology
Matthew S. Davids, Benjamin L. Lampson, Svitlana Tyekucheva, Zixu Wang, Jessica C. Lowney, Samantha Pazienza, Josie Montegaard, Victoria Patterson, Matthew Weinstock, Jennifer L. Crombie, Samuel Y. Ng, Austin Kim, Caron A. Jacobson, Ann S. LaCasce, Philippe Armand, Jon E. Arnason, David C. Fisher, Jennifer R. Brown
Summary: The triplet therapy with acalabrutinib, venetoclax, and obinutuzumab showed promising results in inducing complete remission with undetectable MRD in the bone marrow for patients with chronic lymphocytic leukaemia. Despite not meeting the primary endpoint, the high proportion of patients achieving undetectable MRD supports further investigation into this regimen.
Article
Hematology
Jacob D. Soumerai, Anthony R. Mato, Ahmet Dogan, Venkatraman E. Seshan, Erel Joffe, Kelsey Flaherty, Jason Carter, Ephraim Hochberg, Jeffrey A. Barnes, Audrey M. Hamilton, Jeremy S. Abramson, Connie L. Batlevi, Matthew J. Matasar, Ariela Noy, Colette N. Owens, M. Lia Palomba, Anita Kumar, Tak Takvorian, Ai Ni, Morgan Choma, Chaya Friedman, Puja Chadha, Elizabeth Simkins, Jade Ruiters, Sidney Sechio, Daneal Portman, Lauren Ramos, Natascha Nolet, Neena Mahajan, Rosalba Martignetti, Joanna Mi, Krista Scorsune, Julia Lynch, Brianne McGree, Stephanie Hughes, Clare Grieve, Lindsey E. Roeker, Meghan Thompson, P. Connor Johnson, Mikhail Roshal, Jane Huang, Juliana Biondo, Qun Wu, Allison Jacob, Omar Abdel-Wahab, Andrew D. Zelenetz
Summary: The combination therapy of zanubrutinib with obinutuzumab and venetoclax (BOVen) for chronic lymphocytic leukaemia and small lymphocytic lymphoma is effective in achieving undetectable minimal residual disease (MRD). Despite a median treatment duration of only 10 months, the treatment was well tolerated and met the primary endpoint of the study. This approach shows promise as a potential treatment option for these conditions.
LANCET HAEMATOLOGY
(2021)
Article
Hematology
Lukas Smolej, Yvona Brychtova, Eduard Cmunt, Michael Doubek, Martin Spacek, David Belada, Martin Simkovic, Lukas Stejskal, Irena Zygulova, Renata Urbanova, Martin Brejcha, Jana Zuchnicka, Heidi Mocikova, Tomas Kozak
Summary: The study showed that low-dose FCR is a well-tolerated and effective first-line regimen for selected elderly/comorbid patients with CLL/SLL, particularly those with favorable biology. Neutropenia was a common adverse event, but serious infections were relatively low.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Hematology
Martin Spacek, Lukas Smolej, Martin Simkovic, Lucie Nekvindova, Zlatuse Kristkova, Yvona Brychtova, Anna Panovska, Stanislava Maslejova, Lucie Bezdekova, Dominika Ecsiova, Pavel Vodarek, Jana Zuchnicka, Jana Mihalyova, Renata Urbanova, Peter Turcsanyi, Daniel Lysak, Jan Novak, Martin Brejcha, Tereza Likarova, Prokop Vodicka, Jana Baranova, Marek Trneny, Michael Doubek
Summary: Idelalisib plus rituximab showed inferior efficacy and tolerability compared to ibrutinib in patients with relapsed/refractory CLL, but may still be considered in select cases.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Petra Langerbeins, Can Zhang, Sandra Robrecht, Paula Cramer, Moritz Fuerstenau, Othman Al-Sawaf, Julia von Tresckow, Anna-Maria Fink, Karl-Anton Kreuzer, Ursula Vehling-Kaiser, Eugen Tausch, Lothar Mueller, Michael Josef Eckart, Rudolf Schlag, Werner Freier, Tobias Gaska, Christina Balser, Marcel Reiser, Martina Stauch, Clemens-Martin Wendtner, Kirsten Fischer, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek
Summary: Observation is the standard of care for early-stage asymptomatic chronic lymphocytic leukemia (CLL) patients, as chemotherapy-based interventions have not been effective in prolonging survival. However, early intervention with ibrutinib may lead to superior disease control and is well tolerated. The CLL12 trial showed that ibrutinib significantly improved event-free survival in asymptomatic, treatment-naive early-stage CLL patients at increased risk of progression, without increasing overall toxicity.
Article
Oncology
Paul J. Hampel, Kari G. Rabe, Timothy G. Call, Wei Ding, Jose F. Leis, Asher A. Chanan-Khan, Saad S. Kenderian, Eli Muchtar, Yucai Wang, Sikander Ailawadhi, Amber B. Koehler, Ricardo Parrondo, Susan M. Schwager, Taimur Sher, Curtis A. Hanson, Min Shi, Daniel L. Van Dyke, Esteban Braggio, Susan L. Slager, Neil E. Kay, Sameer A. Parikh
Summary: Patients with chronic lymphocytic leukemia (CLL) who have disease progression on ibrutinib have worse outcomes compared to those who stop ibrutinib due to toxicity. A study evaluated the outcomes of CLL patients with disease progression on ibrutinib and found that overall survival (OS) was longer for patients who received ibrutinib as a frontline treatment and next-line treatments such as chimeric antigen receptor T-cell therapy and venetoclax-based treatment showed better outcomes compared to other approved treatments. These findings suggest a need for better treatment options for CLL patients with disease progression on ibrutinib.
BLOOD CANCER JOURNAL
(2022)
Article
Hematology
Paul J. Hampel, Kari G. Rabe, Timothy G. Call, Wei Ding, Jose F. Leis, Saad S. Kenderian, Eli Muchtar, Yucai Wang, Amber B. Koehler, Ricardo Parrondo, Susan M. Schwager, Min Shi, Esteban Braggio, Susan L. Slager, Neil E. Kay, Sameer A. Parikh
Summary: Patients with disease refractory to commonly used novel agents, such as ibrutinib, may benefit from combined treatment with ibrutinib and venetoclax, as shown in this retrospective study.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Oncology
Robert Szasz, Bela Telek, Arpad Illes
Summary: This study compared the impact of fitness on prolonged cytopenias and reported real-life data on FCR treatment. The findings show a decrease in the number of patients treated with FCR in recent years, likely due to the availability of targeted therapies.
PATHOLOGY & ONCOLOGY RESEARCH
(2021)
Article
Hematology
Paul M. Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A. Burger, Peter Hillmen, Steve E. Coutre, Claire Dearden, Sebastian Grosicki, Helen McCarthy, Jian-Yong Li, Fritz Offner, Carol Moreno, Cathy Zhou, Emily Hsu, Anita Szoke, Thomas J. Kipps, Paolo Ghia
Summary: This study reports long-term follow-up data from the RESONATE-2 phase 3 study of ibrutinib in previously untreated CLL patients. The results show that ibrutinib provides sustained benefit in terms of progression-free survival and overall survival, even in patients with high-risk genomic features.